Search Results

You are looking at 211 - 220 of 2,704 items for :

  • Refine by Access: All x
Clear All
Full access

Current Recommendations for Systemic Therapy of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury and David G. Pfister

. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at www.medscape.org/journal/jnccn ; (4) view

Full access

Stereotactic Radiosurgery and Bevacizumab for Recurrent Glioblastoma Multiforme

Alvin R. Cabrera, Kyle C. Cuneo, James J. Vredenburgh, John H. Sampson, and John P. Kirkpatrick

patients enrolled onto phase II clinical trials . J Clin Oncol 1999 ; 17 : 2572 – 2578 . 8 Reardon DA Turner S Peters KB . A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma . J Natl Compr Canc Netw 2011 ; 9 : 414

Full access

Corticosteroids in the Treatment of Chemotherapy-Induced Nausea and Vomiting

Sally Yowell Barbour

of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at www

Full access

Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer

Eric M. Lander, Xuanyi Li, Li-Ching Huang, Amanda S. Cass, Wade T. Iams, Emily A. Skotte, Jennifer G. Whisenant, Robert A. Ramirez, Sally J. York, Travis J. Osterman, Jennifer A. Lewis, Christine M. Lovly, Yu Shyr, and Leora Horn

strategies aimed at preventing inpatient admissions. Through direct assessment of medical records and a multidisciplinary, consensus-driven review process, we identified clinically relevant risk factors for potentially avoidable hospitalizations (PAHs) and

Full access

Molecular Profiling in Cutaneous Melanoma

Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter

both from a diagnostic and a prognostic perspective, which has led to 2 currently commercially available assays in the United States. This review summarizes some of the ongoing efforts to bring molecular techniques into clinical practice, specifically

Full access

Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal

Van K. Morris and Cathy Eng

are few options for this population, new, effective treatment strategies are warranted. This review highlights the role of immune-based therapies for patients with this HPV-associated malignancy. Anti–PD-1 Therapies In a physiologic state, immune

Full access

Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?

Kamya Sankar and Brady L. Stein

the PT-1 trial were reported, which is a prospective open-label randomized trial evaluating cytoreduction therapy in patients with intermediate-risk ET. 12 This contemporary trial prompted this review, with the goal of presenting existing data for

Full access

How NCCN Guidelines Can Help Young Adults and Older Adolescents With Cancer and the Professionals Who Care for Them

Archie Bleyer

the SEER registry. 1 Specific recommendations for addressing the AYAO challenges were obtained from the Progress Review Group (PRG) report on AYA Oncology (AYAO PRG), co-sponsored by the NCI and the Lance Armstrong Foundation. 3 The AYA age range was

Full access

Impact of Genetic Counseling on Patient-Reported Electronic Cancer Family History Collection

Rebecca A. Vanderwall, Alison Schwartz, Lindsay Kipnis, Catherine M. Skefos, Samantha M. Stokes, Nizar Bhulani, Michelle Weitz, Rebecca Gelman, Judy E. Garber, and Huma Q. Rana

(DFCI) Institutional Review Board. Patients are referred to the Division of Cancer Genetics and Prevention at DFCI for CGC related to a personal and/or family history of cancer. At the time of this study, patients with cancer treated by DFCI oncologists

Full access

Role of Immunotherapy in Triple-Negative Breast Cancer

Tanya E. Keenan and Sara M. Tolaney

cells to mount an antitumor immune response, 16 which can be strengthened by ICIs. 17 This review presents a framework for understanding the current clinical experience surrounding ICIs and other novel immunotherapy agents in TNBC ( Figure 1 ). In